Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Incyte Corporation    INCY

INCYTE CORPORATION (INCY)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/08/2017 12/11/2017 12/12/2017 12/13/2017 12/14/2017 Date
96.58(c) 97.25(c) 95.4(c) 98.1(c) 95.97(c) Last
1 339 633 1 363 813 1 548 638 1 323 276 1 303 802 Volume
+1.85% +0.69% -1.90% +2.83% -2.17% Change
More quotes
Financials ($)
Sales 2017 1 501 M
EBIT 2017 -215 M
Net income 2017 -263 M
Finance 2017 466 M
Yield 2017 -
Sales 2018 1 740 M
EBIT 2018 30,4 M
Net income 2018 51,1 M
Finance 2018 1 007 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018 1 329,27
EV / Sales2017 13,5x
EV / Sales2018 11,3x
Capitalization 20 703 M
More Financials
Company
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics.Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized products JAKAFI (ruxolitinib), and... 
More about the company
Surperformance© ratings of Incyte Corporation
Trading Rating : Investor Rating :
More Ratings
Latest news on INCYTE CORPORATION
02:01p INCYTE : to Present at Upcoming Investor Conference
12/13 Aduro discontinues development of CRS-207
12/11 INCYTE CORPORATION : (INCY) Position Boosted by Capital Bank & Trust Co
12/10 INCYTE : Four-Year Phase 3 Data Analysis Shows Durability of Response of Jakafi®..
12/10 INCYTE : Study shows Incyte's Jakafi is effective in long-term treatment of rare..
12/08 IMMUNOVACCINE : Immuno-Oncology Candidate Yields `Impressive` Early Clinical Res..
12/07 MACROGENICS : Announces Closing of MGA012 Global Collaboration and License Agree..
12/06 IMMUNOVACCINE : Announces Positive Clinical Data from Its Collaborative Combinat..
12/05 IMMUNOVACCINE : to Hold Webcast and Conference Call to Discuss Clinical Data Fro..
11/30 NASDAQ 100 MOVERS : Nclh, incy
More news
Sector news : Biotechnology & Medical Research - NEC
12/13 France's Sanofi pins hopes on new drugs after setbacks
12/12 Sanofi investors hungry for drug progress and deal news
12/09 Tax-loss selling to pressure 2017's losers in December
11/30 GENMAB : and J&J 'love' partnership as some ponder takeover
11/27 MERCK AND : As Brexit looms, UK pitches new industry plan, wins support from Mer..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
04:07a YOUR DAILY PHARMA SCOOP : Right Time To Buy Regeneron, Eli Lilly Gives Guidance,..
12/12 ROTY EDITION 1 VOLUME 61 : ASH Updates And Trades
12/10 BIOTECH IN 2018 : Will Repatriated Cash Fuel A Feeding Frenzy?
12/08 YOUR DAILY PHARMA SCOOP : Geron Update, Acorda Resubmits NDA, Sage Rallies
12/07 ROTY EDITION 1 VOLUME 59 : Updates And Trades
Chart INCYTE CORPORATION
Duration : Period :
Incyte Corporation Technical Analysis Chart | INCY | US45337C1027 | 4-Traders
Technical analysis trends INCYTE CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 149 $
Spread / Average Target 52%
EPS Revisions
Managers
NameTitle
Hervé Hoppenot Chairman, President & Chief Executive Officer
David W. Gryska Chief Financial Officer & Executive Vice President
Reid M. Huber Chief Scientific Officer & Executive VP
Steven H. Stein Chief Medical Officer & Executive Vice President
Paul Alan Brooke Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
INCYTE CORPORATION-3.68%20 703
CELLTRION, INC.--.--%23 699
IQVIA HOLDINGS INC32.70%21 261
LONZA GROUP57.44%20 102
ALNYLAM PHARMACEUTICALS, INC.249.60%12 278
NEKTAR THERAPEUTICS339.85%8 917